Develops and commercializes therapeutics for patients with kidney disease, focusing on anemia and iron deficiency.
Akebia Therapeutics, Inc., a prominent biopharmaceutical firm, specializes in advancing and commercializing innovative therapies tailored for patients suffering from kidney diseases. At the forefront of its portfolio is vadadustat, an oral investigational therapy currently undergoing Phase III development. This drug aims to address anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis dependent adult patients, reflecting Akebia's commitment to improving outcomes in renal health.
In addition to vadadustat, Akebia Therapeutics offers Auryxia, a ferric citrate medication designed to manage serum phosphorus levels in adult patients with dialysis-dependent CKD. Auryxia also serves as a treatment for iron deficiency anemia in adult CKD patients not on dialysis, further demonstrating the company's comprehensive approach to addressing diverse aspects of kidney-related conditions.
Established in 2007 and headquartered in Cambridge, Massachusetts, Akebia Therapeutics has forged strategic collaborations to enhance its global presence and accelerate therapeutic developments. Partnerships with Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, and Janssen Pharmaceutica NV underscore Akebia's collaborative efforts in advancing vadadustat across major international markets, reinforcing its pivotal role in the evolution of kidney disease treatments worldw ide.